CHALLENGE:

The sponsor of an early phase, industry landmark (KEYNOTE-21) NSCLC trial needed a data-led approach to optimize protocol design and identify highest enrolling countries and sites. Competition for patients was high.

SOLUTION:

Phesi’s Trial Accelerator™ platform, driven by the world’s largest trial database, was used to: 

  • Analyze and optimize key protocol design elements (ECOG performance status, disease stage, life expectancy and after steroid use).
  • Assess the operational impact from key protocol design elements on enrollment cycle time, country and investigator site selection.
  • Identify top enrolling investigator sites.
  • Baseline analysis of 550 NSCLC trials showed that enrollment cycle time was 750 days for this complex, early phase trial.
  • Through identification of highest performance sites using the Phesi platform ECT was forecast at 650 days.
  • Patient enrollment completed in 670 days. 

THE DATA:

IMPACT:

Phesi’s approach supported internal decision making on design, selection of highest enrolling countries and investigator sites and accurate forecast of enrollment cycle time in this landmark study.

 

Request a demo and find out how Phesi can help
you achieve smarter trials and faster cures

 

 

 

Related cases
03. 14. 2023
Protocol Design and Investigator Site Selection: Type 2 Diabetes Mellitus (T2DM) Read more
03. 14. 2023
Protocol Optimization and Study Feasibility: Iron Overload Integrated Development Plan, Phase 1B Trial Read more
03. 14. 2023
Protocol Planning: Inotuzumab Ozogamicin In Acute Lymphoblastic Leukemia (ALL) Read more
03. 14. 2023
Protocol Design and Investigator Site Selection: Phase III Osteoarthritis Pain of the Knee Trial Read more
03. 06. 2023
Protocol Design and Investigator Site Selection: Follicular Lymphoma Read more